Clinical Trial

A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

Withdrawn Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
PI requested
Summary
To find safe and effective doses of lisaftoclax and pelcitoclax in combination with FLAG chemotherapy in patients with relapsed/refractory T-ALL.
Protocol Amendment History 5 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-05-08
critical Reason stopped changed: — → PI requested 2026-05-08
notable Enrollment reduced: 24 -> 0 participants 2026-05-08
notable Primary completion moved earlier: 2030-06-12 -> 2026-04-27 2026-05-08
minor Completion moved earlier: 2032-06-12 -> 2026-04-27 2026-05-08
Trial Details
NCT Number NCT07428486
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Ascentage Pharma Group Inc.
Conditions Phase I, FLAG Chemotherapy, Lisaftoclax, Pelcitoclax, Relapsed/Refractory, Lymphoblastic Leukemia Acute
Start Date 2026-04-27
Primary Completion 2026-04-27 (estimated)
Study Completion 2026-04-27 (estimated)
Updated on ClinicalTrials.gov 2026-05-07